156. Transl Oncol. 2018 Apr;11(2):366-373. doi: 10.1016/j.tranon.2018.01.024. Epub2018 Feb 20.A Single Domain-Based Anti-Her2 Antibody Has Potent Antitumor Activities.Wu X(1), Chen S(2), Lin L(3), Liu J(4), Wang Y(5), Li Y(6), Li Q(7), Wang Z(8).Author information: (1)School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China510006; Center for Cellular & Structural Biology, Sun Yat-Sen University,Guangzhou, China 510006. Electronic address: wuxq23@mail2.sysu.edu.cn.(2)School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China510006; Center for Cellular & Structural Biology, Sun Yat-Sen University,Guangzhou, China 510006. Electronic address: chen.sqi@outlook.com.(3)School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China510006; Center for Cellular & Structural Biology, Sun Yat-Sen University,Guangzhou, China 510006. Electronic address: linlm3@mail2.sysu.edu.cn.(4)School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China510006; Center for Cellular & Structural Biology, Sun Yat-Sen University,Guangzhou, China 510006. Electronic address: liujy53@mail2.sysu.edu.cn.(5)School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China510006; Center for Cellular & Structural Biology, Sun Yat-Sen University,Guangzhou, China 510006. Electronic address: wangylan3@mail2.sysu.edu.cn.(6)School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China510006; Center for Cellular & Structural Biology, Sun Yat-Sen University,Guangzhou, China 510006. Electronic address: liym45@mail2.sysu.edu.cn.(7)School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China510006; Center for Cellular & Structural Biology, Sun Yat-Sen University,Guangzhou, China 510006. Electronic address: liqing66@mail.sysu.edu.cn.(8)School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China510006; Center for Cellular & Structural Biology, Sun Yat-Sen University,Guangzhou, China 510006. Electronic address: wangzh357@mail.sysu.edu.cn.Human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately20% to 30% of breast cancers and various other types of cancers, which plays avital role in the cancer progression. Monoclonal antibodies targeting Her2 arenow used in the clinic to treat Her2 overexpression cancer patients. However,relapse or resistance is frequent with the current therapies. To generate a newtreatment avenue against Her2, we immunized and selected a specific anti-Her2single domain antibody C3 for further studies. The C3-Fc antibody droveantibody-dependent cell-mediated cytotoxicity against Her2-positive tumor cellsin vitro and resulted in potent antitumor growth in vivo. These data suggest thatthe C3-Fc antibody may provide an alternative avenue for Her2-positive cancertherapy.Copyright Â© 2018. Published by Elsevier Inc.DOI: 10.1016/j.tranon.2018.01.024 PMCID: PMC5852409PMID: 29455083 